Pharma
Commented by Stefan Feulner on January 14th, 2025 | 07:55 CET
Qiagen, Vidac Pharma, and Bayer with groundbreaking news
In the years to come, biotechnology will play a central role in solving global challenges. From the development of innovative therapies to sustainable agriculture and biobased industries, biotechnology combines science and technology to make the world more sustainable and efficient. As a driver of growth and innovation, it offers enormous opportunities for companies and investors who want to actively shape the future.
Read
Commented by Armin Schulz on January 8th, 2025 | 07:30 CET
Bayer, First Hydrogen, Volkswagen – Turnaround Candidates for 2025 Under Review
After the year-end portfolio window-dressing in December, the new year starts with the hunt for the right stocks for 2025. Special attention should be given to turnaround candidates, meaning stocks that underperformed last year. These companies have faced challenging times and have often already begun addressing their issues through strategic realignment. Sometimes, market conditions for a sector can improve significantly from one year to the next, and then the stocks of these companies often rise disproportionately. Identifying the right stocks requires thorough research. We look at three potential turnaround candidates.
Read
Commented by André Will-Laudien on January 6th, 2025 | 07:00 CET
Biotech-Rally 2025: Evotec, BioNTech, Vidac Pharma, Pfizer and Bayer are on the buy list
For two years, there was almost no movement in the biotech sector. Not even the trend of falling interest rates that began in 2024 could persuade investors to make larger investments. Meanwhile, AI and high-tech stocks continued to perform well, driving the Nasdaq 100 index up by over 30%. However, in the last quarter of 2024, some bombed-out life sciences stocks saw significant markups, and new takeover rumours also began circulating. Whether the sentiment can continue to rise in the coming weeks is something we will explore further. Let's take a closer look at our top picks for 2025.
Read
Commented by Armin Schulz on January 3rd, 2025 | 07:00 CET
D-Wave Quantum, ARI Motors, Bayer – Which stocks should be in the portfolio for 2025?
After Google presented its quantum processor, Willow, D-Wave Quantum's shares skyrocketed. The question is how sustainable this increase is and whether quantum computing will be the next big hype after artificial intelligence. For the automotive industry, 2024 was a year to forget. Many automakers are currently struggling with problems. ARI Motors, an electric vehicle manufacturer that has secured a niche for itself, is faring better. Will the entire automotive industry manage a turnaround in the coming year? Bayer's shareholders are also hoping for a turnaround. The share price took a significant hit last year. 2025 is expected to be much better. We take a closer look at the individual stocks.
Read
Commented by Fabian Lorenz on January 2nd, 2025 | 07:15 CET
MOMENTUM stocks for 2025: Rheinmetall, Bayer, Almonty Industries - Should you buy now?
Rheinmetall and Almonty Industries are entering the new year with momentum and are on the hunt for new all-time highs: Almonty is one of the strong performers in the commodities sector in 2024, and 2025 should be even better. The Company plans to bring the largest tungsten mine outside of China into production. Based on the explosion in sales and profits in the coming years, analysts see more than 200% upside potential. Things are also going well at Rheinmetall. The defense company plans to double its profit by 2027, suggesting the stock is not expensive. However, there is also potential for a setback. Unfortunately, Bayer experienced only downward momentum in 2024. Is a turnaround in sight for the once-largest DAX company?
Read
Commented by Juliane Zielonka on December 23rd, 2024 | 11:55 CET
Pharma stocks in focus: Setback for Novo Nordisk, spot-on performance for Vidac Pharma and Bayer
Updates from the pharmaceutical and biotech sector for investors: The Danish company Novo Nordisk is experiencing a setback in the development of its new weight loss drug, CagriSema. Vidac Pharma and Bayer, on the other hand, have positive news to report. The biotech company has received an extension of patent protection for its innovative cancer drugs from the US Patent Office, presenting a unique opportunity for investors. Bayer is also celebrating a success: the higher-dose version of the eye drug Eylea has delivered convincing results in the latest study. This means that in the future, patients will require less frequent injections into the eye. We take a closer look at the developments.
Read
Commented by Fabian Lorenz on December 20th, 2024 | 08:00 CET
CAUTION advised for Rheinmetall! COMEBACK for Bayer and Saturn Oil + Gas?
Christmas came a week early for Rheinmetall. Germany's largest defense company has secured further orders worth EUR 1.7 billion. However, investors are reacting cautiously, as a slump could be imminent. In contrast, the downside risk for Saturn Oil & Gas appears limited, with significant upside potential. As one of North America's most cost-effective oil producers, Saturn aims to generate total free cash flow of up to CAD 475 million over three years. Analysts’ targets represent a tripling of the share price. And what is Bayer doing? The Leverkusen-based company is trading close to its multi-year low. However, one analyst outlines an interesting scenario.
Read
Commented by Armin Schulz on December 17th, 2024 | 07:15 CET
TUI share takes off – When will Almonty Industries and Bayer follow suit?
At the end of 2024, the stock market is characterised by a dynamic spirit of optimism, driven by encouraging share price developments and optimistic future prospects. While some companies are showing impressive share price increases, it remains to be seen whether this positive trend will also spread to other sectors or companies. Global developments such as technological advances, sustainable investment strategies and geopolitical dynamics shape the market environment just as much as macroeconomic factors. In particular, interest rate cuts and declining inflation create tailwinds for investors.
Read
Commented by Juliane Zielonka on December 13th, 2024 | 07:00 CET
Medical milestones from Novo Nordisk, BioNxt and Bayer: New hope for millions of patients
Medical research is currently making remarkable progress in the treatment of serious diseases. Three companies in this field are reporting important developments that could improve the lives of many people: the Danish pharmaceutical company Novo Nordisk is consolidating its leading position in the fight against obesity with a market share of over 30% in GLP-1 drugs and is driving global expansion. At the same time, the Canadian company BioNxt Solutions is developing a groundbreaking MS therapy: an innovative and simple administration could significantly ease the daily medication routine for MS patients. Bayer, in turn, is starting an important study for a novel cancer drug that is expected to be particularly effective against aggressive tumour types due to its unique mechanism of action. The specific benefits offered by the new therapies and how they change patients' lives are factors that investors should consider when making their next investment decisions.
Read
Commented by Stefan Feulner on December 10th, 2024 | 07:30 CET
Novo Nordisk, BioNxt Solutions, Bayer – The market continues to boom
The weight-loss drug market was one of the fastest-growing sectors in the past year and shows no signs of slowing down in 2025. Companies like Novo Nordisk have seen their valuations multiply in recent years, significantly boosting their market capitalization. At the same time, smaller life sciences companies in the second tier, such as those with breakthrough technologies, offer interesting entry opportunities.
Read